Fitish review

Standard injections display $219 semaglutide with B6 and $339 tirzepatide for a monthly supply, with consultation and shipping described as included. Microdose products separately list $179 and $269 for 28 days. Oral tirzepatide is $339 for a supply described as four weeks. These are distinct formulations and doses; the standard injection page does not establish one universal 28-day billing period. Confirm the actual supply, recurring charge and any exclusions for the chosen product.

Fitish describes future autobilling controls in its portal and cancellation before a refill is sent to the pharmacy. Its clinic FAQ also permits certain pre-fill cancellations and no-cost appointment cancellation with at least 24 hours’ notice. A later clause, however, calls completed purchases final except for verified errors. Confirm which rule applies to your payment and prescription status. Stopping a future refill does not itself establish a refund for an order already purchased or processed.

The clinical-platform privacy section identifies Fitish, LLC, a Texas LLC, with an address at 2311 East Loop 820 North in Fort Worth. That corrects an older impression that no business address was published. It does not identify your treating practice, current clinician license or dispensing pharmacy. Ask for the actual prescription destination and formulation. The separate address in a dated FDA letter should not be substituted for a verified current filling facility.

Consultation, ongoing portal questions and check-ins are described, while a live appointment depends on state requirements. No universal funded patient bloodwork panel or fixed number of live follow-ups was established. Published product lab results are not patient laboratory benefits. Insurance is not accepted; HSA or FSA use depends on your administrator and payment eligibility. Obtain the testing plan and any additional costs before assuming the advertised medication amount covers all care.

No equivalence was established by these public offers. The microdose program uses a separate fixed low starting dose, and oral tirzepatide is described as an oral tablet in one section and sublingual in another. There is no FDA-approved oral tirzepatide product. Evidence for an approved injection cannot establish absorption, effectiveness or safety for a different compounded formulation. The prescriber and dispenser should clarify the exact product and clinical rationale, without treating cosmetic or wellness marketing as demonstrated benefit.

Confirm the product’s availability in your location and the assigned pharmacy rather than borrowing another treatment’s state exclusions. Public timing estimates combine review, preparation and transit in different ways; overnight shipping begins after dispatch. The refund FAQ asks for error photos within 10 days of original purchase or receipt and reviews claims individually, so clarify the deadline and remedy. The June 2026 FDA warning concerns compounded-drug marketing; it does not establish a selected batch’s quality, a current case outcome or that every treatment is available.